Relay Therapeutics, Inc. RLAY Research and development expense
Research and development expense at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s research and development expense?
- Relay Therapeutics, Inc. (RLAY) reported research and development expense of $70.56M in Q1 2026.
- How has Relay Therapeutics, Inc.'s research and development expense changed year-over-year?
- Relay Therapeutics, Inc.'s research and development expense decreased by 4.4% year-over-year, from $73.81M to $70.56M.
- What is the long-term trend for Relay Therapeutics, Inc.'s research and development expense?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s research and development expense has grown at a 10.9% compound annual growth rate (CAGR), from $172.65M to $261.38M.